Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Chiron/Ciba

Executive Summary

Chiron/Ciba: Firms enter research collaboration with New York University for NYU's optical DNA mapping technology. Chiron and its 49% shareholder Ciba believe that the optical mapping approach "is dramatically faster than existing methods" and requires only "engineering advances in chamber design, streamlined image analysis and software programming in order to maximize throughput" in order to have commercial application for disease research and other uses. Chiron will have exclusive licensing rights to commercialize the technology. Ciba and Chiron both have other collaborations in the genomics field, with Ciba recently signing a $60 mil. agreement with Myriad and Chiron in the process of acquiring the gene therapy company Viagene ("The Pink Sheet" May 8, T&G-13)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026192

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel